Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Monica F ChenZihe SongHelena Alexandra YuLecia V SequistChristine M LovlyEdith P MitchellJeffrey A MoscowRobert C GrayVictoria WangLisa Meier McShaneLawrence V RubinsteinDavid R PattonP Mickey WilliamsStanley R HamiltonYoshie UmemuraJames V TricoliBarbara A ConleyCarlos L ArteagaLyndsay N HarrisPeter J O'DwyerAlice P ChenKeith T FlahertyPublished in: JCO precision oncology (2024)
D770_N771insSVD mutation. Osimertinib was well tolerated and had a safety profile consistent with previous studies.